#Global Trends – HEALTHCARE INSIGHTS

Key Development Disc Medicine has reported positive Phase 3 results for bitopertin, its investigational oral treatment for erythropoietic protoporphyria (EPP),... Read more

Tag: #Global Trends

ASTELLAS SIGNS $400M-PLUS AI PROTEIN DISCOVERY DEAL: WHY PHARMA IS MOVING FROM FINDING MOLECULES TO ENGINEERING MEDICINES BY DESIGN

ASTRAZENECA–AMGEN’S TEZSPIRE ACHIEVES 69% REMISSION IN ESOPHAGEAL DISEASE: WHY MULTI-INDICATION BIOLOGICS ARE RESHAPING THE IMMUNOLOGY MARKET

ROCHE ADVANCES THREE ONCOLOGY PLATFORMS AT ESMO 2026: WHY THE NEXT CANCER DRUG BATTLE IS ABOUT CLINICAL DIFFERENTIATION, NOT PIPELINE SIZE

HIMS & HERS EXPANDS WEIGHT MANAGEMENT INTO GERMANY: WHY TELEHEALTH IS RESHAPING THE COMMERCIAL VALUE CHAIN OF OBESITY TREATMENT

NOVO NORDISK’S CAGR ISEMA DELIVERS 25% WEIGHT LOSS IN WOMEN: WHY THE NEXT OBESITY DRUG BATTLE WILL BE FOUGHT OVER CLINICAL DIFFERENTIATION, NOT HEADLINE EFFICACY

PENNSYLVANIA MEASLES CASES REACH 1,286: WHY VACCINATION COVERAGE, NOT VACCINE AVAILABILITY ALONE, IS THE NEXT PUBLIC HEALTH CHALLENGE

DISC MEDICINE REBOUNDS FROM FDA REJECTION WITH PHASE 3 SUCCESS: WHY CLINICAL BENEFIT, NOT BIOMARKER IMPROVEMENT ALONE, IS THE REAL CURRENCY OF DRUG APPROVAL

GILEAD’S ORAL IBD DRUG ACHIEVES 31% REMISSION: THE NEXT IMMUNOLOGY BATTLE MAY BE WON BY COMBINING BIOLOGIC PRECISION WITH PILL CONVENIENCE

NOVARTIS HALTS FABHALTA LUPUS NEPHRITIS TRIAL: WHY INDICATION EXPANSION IS BECOMING A CAPITAL ALLOCATION TEST IN KIDNEY DRUG DEVELOPMENT

Facebook

Map

Online Members